MedTrace Logo

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

NCT05645744 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2024-07-22

No results posted yet for this study

Summary

A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.

Conditions

  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
  • Chronic Lymphocytic Leukemia in Relapse
  • Small Lymphocytic Lymphoma, Relapsed
  • Waldenstrom's Macroglobulinemia Recurrent
  • Follicular B-cell Non-Hodgkin's Lymphoma
  • B-cell Lymphoma Refractory
  • Mantle Cell Lymphoma Recurrent
  • Hairy Cell Leukemia
  • Diffuse Large B Cell Lymphoma
  • Waldenstrom's Macroglobulinemia Refractory
  • Mantle Cell Lymphoma Refractory

Interventions

BIOLOGICAL

Prior MB-102 CAR-T cell investigational product.

No investigational product will be administered.

BIOLOGICAL

Prior MB-106 CAR-T cell investigational product.

No investigational product will be administered.

Sponsors & Collaborators

  • Mustang Bio

    lead INDUSTRY

Principal Investigators

  • Bruce Dezube, M.D. · Mustang Bio

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-29
Primary Completion
2024-04-12
Completion
2024-04-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05645744 on ClinicalTrials.gov